Medication, Weight Gain and GI Hormones
Completed · Phase 4
Conditions studied: Bipolar Depression
In brief
This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication. Both medications are used to treat depressed bipolar patients. The main focus of this study is the comparison of these two medications on gastro-intestinal hormones and weight gain.
Key facts
- Study ID
- NCT00384332
- Run by
- Vanderbilt University
- People needed
- 20
- Starts
- 2007-01-01
- Expected to finish
- 2010-03-01
- Last updated by the study team
- 2017-07-31
Who can join
Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- A principal diagnosis of bipolar 1 or II disorder
- Ages 18-60
- Physically healthy
- Outpatient status
- Montgomery-Asberg Rating Scale (MADRS) Score greater than or equal to 15
- BMI 23-30
- Able and willing to give written informed consent
You may not qualify if…
- Prior history of diabetes (types I or II)
- BMI>30
- Non-fasting blood glucose >124
- Fasting blood glucose >125 or random blood glucose >200
- Presence of dyslipidemia (baseline total cholesterol >240, HDL<50, LDL>160, triglycerides >199)
- Current or past history of a non-affective psychotic disorder
- Alcohol or other substance abuse or dependence in the 6 months prior to the evaluation (except for caffeine)
- Current use of any nicotine products
- Schizoid, schizotypal, or borderline personality disorder
- Treatment with olanzapine in the prior 3 months or any history of non- response to or intolerance of olanzapine or the olanzapine-fluoxetine combination (SymbiaxTM)
- Suicide potential that, in the opinion of the investigator, precludes outpatient treatment or participation in a trial
- Participation of subjects in another drug trial within 30 days of evaluation
- The presence of any current medical condition judged by the investigator to potentially interfere with the study procedures or measures
- The likelihood of requiring hospitalization over the period of the study
- The presence of any clinically-significant laboratory abnormality as judged by the investigator
- Pregnancy or lactation
- History of seizure disorder, excluding febrile seizures of childhood
- Any disorder of taste or smell, including severe nasal allergies
- Any other condition which, in the investigator's judgment might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study
- Being unable to comprehend or follow the study procedures.
Where it is running
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.